


**Clinical profile of pediatric oncology patients**  
*managed and treated in Children's & Adolescent's Hematology - Oncology Unit of*  
*2<sup>nd</sup> Paediatric Department,*  
*School of Medicine, Aristotle University of Thessaloniki,*  
*AHEPA General University Hospital, Greece*

Emmanouel Hatzipantelis  
Professor in Paediatrics & Paed Haematology-Oncology  
Head, Children's & Adolescent's Hematology-Oncology Unit of  
B' Paediatric Department, School of Medicine,  
Aristotle University of Thessaloniki

# GREECE
























Photopress©Yannis Tsouflidis




Photopress©Yannis Tsouflidis

# CASES OF CHILDHOOD CANCER IN THESSALONIKI FROM 1990-2008






### Numbers of childhood malignancies 1991-2011





## Frequency of childhood malignancies 1991-2011





## ALL (UKALL XI protocol)

98 children from 1993 to 2001 treated with UKALL XI protocol.

28 /98 (29,6%) relapsed, 19 boys and 9 girls (mean age 8yrs).

3-74 months (26) months from diagnosis, BM 15 , CNS 9 , testicular 2 , BM/CNS 2.

< 6 months from diagnosis 5 , >6 months to 6 after therapy 13, >6 months after therapy 10.

Received chemotherapy with BFM 90 and BFM 96 protocols.

2<sup>nd</sup> remission achieved in 24/28 (85,7%) children.

15/24 underwent allogeneic SCT

10/24 stay in remission for more than 5 years.

14 /24 second relapse, 2 of them are in 3<sup>rd</sup> remission for >3 yrs.

**OS 83%, EFS 72%**

## AML

17 children, 8 boys and 9 girls , mean age 6,4 yrs.

1 AML M0, 5 M1, 7 M2, 2 M3 , 2 M5.

15 out of 17 received MRC, AML – 12 protocol (ADE X 2, MACE, MiDAC X2)

M3 AML patients received ATRA /anthracyclins  
5 patients underwent SCT

10 / 17 alive for more than 3 years

**IN TOTAL 66  
PATIENTS  
OS: 50%**

## ALL (ALL-BFM 95 protocol)

50 patients were treated from September 2001 to August 2005 according to the ALL – BFM 95 protocol, 24 boys and 26 girls, median age 6,5 years

standard risk group 12(24%), median 32(64%) and high risk 6(12%).

39/49 are in 1<sup>st</sup> CR from 1,5 to 5 yrs after therapy.

2 died from sepsis during induction/reinduction chemo,

7 relapsed (5 HR) 3 – 34 months from diagnosis.

4 underwent SCT.

3/7 remain in 2<sup>nd</sup> CR for >2 yrs from relapse.

**OS 85%, EFS 79%**

**IN TOTAL 300 CHILDREN TREATED  
WITH BFM-95, BFM-2000  
AND LAST 2 YEARS WITH ALLIC 2009**



# Hodgkin disease

From 1980-2005 74 children, aged 4-15 (median age 10.8), 50 boys and 24 girls.

49 (66%) of children were grouped in mixed cellularity subtype, 23 (31.5%) in nodular sclerosis subtype and 2 (2.5%) in lymphocytic depletion subtype.

Ann Arbor staging classification: 8 (10.8%) → stage I, 35 (47.3%) → II, 28 (37.8%) → III, 3 (4%) → IV.

All patients have been treated with chemotherapy (MOPP 14, MOPP ABVD 8, CVIPP 27 and ABVD 25 children).

14 (19%) relapsed, chemotherapy as well as radiotherapy were applied, 6 patients underwent autologous SCT. OS 94.5%, EFS 89%.

**IN TOTAL 117 PATIENTS, OS 94%  
NOW EURONET PHL R COPP/COPDAC**

# Non Hodgkin Lymphomas

60 children with NHL, 34 B-cell NHL, 18 T-cell NHL, 8 Ki-1 ALCL.

**B-NHL:** 26 boys and 8 girls, mean age 6 yrs. Treated with 901, 902, 903 UKCCSG-NHL protocols. 4 underwent ASCT. OS (>3yrs) 85%.

**T-NHL:** 15 boys and 3 girls, mean age 7,5 yrs. Treated with MRC 904 protocol. 3 patients that relapsed underwent megatherapy/ASCT and 1 allogeneic SCT. OS: 78% (>4 yrs)

**Ki-1 ALCL:** 8 children (7 boys and 1 girl), with a mean age of 10,5 yrs.

Treated with HN97 (6), NHL-BFM 90 (2), 1 plus local irradiation. All alive >3yrs

Total OS 83%, 50/60 children alive for more than 3 yrs.

**IN TOTAL 85 CHILDREN**

# **CNS TUMORS**

<10%, 132 PATIENTS

????????????????????



# Renal tumours

60 children, 25 boys and 35 girls, mean age 3,5 years.

53 (88,3%) Wilms tumour, 7 (11,66%) others (2 clear cell sarcoma, 2 carcinoma, 2 rhabdoid tumour, 1 nephroblastomatosis).

**WILMS patients:** 19 (35,8%) stage I, 18 (33,96%) stage II, 9 (16,96%) stage III, 4 (7,55%) stage IV, and 3 (5,66%) stage V.  
83% favorable histology

All surgical resection, 57 chemotherapy (UKW3), 18 radiotherapy.

OS >3 years 51/60 (85%), 46 (86,7%) Wilms

**IN TOTAL 81 PATIENTS, SIOP WT 2001**

## NEUROBLASTOMA

- 102 patients, 9%
  - Gaglio.....
- Stage I ,II →95%
- Stage III →50%
- Stage IV →.....
- Stage Ivs →100%
- **SIOPEN R-NET**

# Rhabdomyosarcoma

25 children ,15 boys and 10 girls, with a mean age: 5,8 years.

Embryonal type 16/25 (64%), alveolar type 7/25 (28%), 2/25 (8%) undifferentiated

stage I 2/25 (8%), stage II 5/25 (20%), stage III 11/25 (44%), stage IV 7/25 (28%).

Surgical resection, chemotherapy (MMT 89/ MMT 95) and radiotherapy.

OS 60%, stage III 45,5%, stage IV 43%

**IN TOTAL 46 children**

# Non RMS Soft tissue Sarcomas

12 children with NRSTS, 6 boys and 6 girls, mean age 5 years.  
2 synobial sarcoma, 4 extraosseous Ewing, 2 fibrosarcoma, 1 haemoangiopericytoma, 1 liposarcoma, 1 malignant fibrous histiocyoma, and 1 chondrosarcoma.

surgical resection and/or chemotherapy (vinc+doxo+cyclo / ifos+etoposide) and/or radiotherapy.

8/12 patients alive for more than 5 years .  
4/12 died (1 fibrosarcoma, 1 extraosseous Ewing, 1 malignant fibrous histiocyoma, 1 chondrosarcoma)



## **OSTEOSARCOMA**

**20 patients**

**EURAMOS**

**OS 55%**

# **Ewing Sarcoma**

18 children with Ewing sarcoma, 9 boys and 9 girls  
aged 3-14 years (mean age 8 yrs).

All received chemotherapy with EICESS-92 protocol,  
11/18 surgical resection, 9/18 irradiation.

**10/18 alive for more than 3 years (OS 55,5%)**

**IN TOTAL 48 children**  
**EURO EWING 99**

# Germ cell tumours

20 children , 12 girls and 8 boys, mean age 7 yrs.  
7 yolk sac tumours, 2 dysgerminomas, 1 choriocarcinoma,  
9 teratomas and 1 mixed.  
(6 were extragonadal)  
AFP raised in 11/20 (55%) children,  $\beta$ -HCG raised in 2  
patients with choriocarcinoma/mixed.

Stage I  $\rightarrow$  4, II  $\rightarrow$  6, III  $\rightarrow$  5 , IV  $\rightarrow$  5 children.

Stage I tumours treated with surgical resection.

Stage II or more  $\rightarrow$  resection followed by chemotherapy  
(10  $\rightarrow$  JEB , 6  $\rightarrow$  VAC).

3 patients received irradiation.

Alive 16/20 children, 3,5 to 20 yrs from diagnosis (80%).

**IN TOTAL 40 children**

# Liver tumors

**18 hepatoblastoma**, mean age of 2 years old.

4 stage I, 7 stage II, 5 stage III and 2 stage IV.

3 received cyclophosphamide and vincristine and 12  
cisplatin and doxorubicin.

## **SIOPEL protocol**

Full surgical removal of the tumour managed in 4/18  
patients with stage I and 8/18 with stage II/III.

13 out of 18 patients survive free of disease 2 to 24  
years after diagnosis.

**5 hepatocellular carcinoma**, mean age of 6 years ,  
2 stage II, 1 stage III and 2 stage IV.

They all received chemotherapy with cisplatin and  
doxorubicin.

Full surgical excision managed in 4/5 patients.

Two patients survived, one of them after liver  
transplantation. The other 3 have died because of  
relapse and progress of the disease.



# **Carcinoid tumour of the appendix**

**19 children, 9 boys and 10 girls with a mean age of 10,5 year-old**

In 18 out of 19 children the size of the tumor was less than 1cm in diameter, and did not infiltrate the surrounding tissues.

Staging of the disease included abdominal ultrasound, chest and abdominal CT, liver and spleen scan, Tc99 bone scan, urine 5-HIAA levels, and in 10 patients In111 Octreotide scan.

All children were free of metastatic disease and no further surgical or other therapeutic intervention was needed.

**No patient relapsed for a period of 2-22 years from diagnosis.**

# **Langerhans Cell Histiocytosis**

27 children, 17 boys and 10 girls, mean age of 6 yrs (range 2mo-13yrs).

20 patients had single-system disease and 7 had multisystem disease .

9 pts had unique bone disease, 11 had multifocal bone disease. Central diabetes insipidus was observed in 3 patients lymph nodes were involved in 6, middle ear and mastoids were involved in 3 and lungs were involved in 2 patients.

Treatment comprised chemotherapy in 17pts (DAL-HX-90, LCH-I, LCH-II, LCH-III), surgery in 5 pts, 2 pts received low dose irradiation, while 8 pts didn't take any therapy. 1 patient underwent (sibling) SCT.

Relapse was observed in 7 pts. Five pts had 2-6 reactivations (3mo-4yrs from the diagnosis).

4 pts with multisystem disease and 1 with pulmonary LCH died. 25 patients are alive (86%) , 1 to 18 yrs from diagnosis.



**IN TOTAL 45 patients, LCH-III PROT**

Children's & Adolescents Haematology/Oncology Unit,  
2<sup>nd</sup> Paediatric Department of Aristotle University of  
Thessaloniki, School of Medicine,  
AHEPA General University Hospital, Greece

**From 2009 to 2023**




**532 PATIENTS AGED 1-16 YEARS  
APPROXIMATELY 35 NEW CASES PER YEAR**




# HEMATOLOGICAL MALIGNANCIES

■ ALL ■ AML ■ CML/MDS ■ HLH




*HEMATOLOGICAL MALIGNANCIES - OS*




# LYMPHOMAS

■ HL ■ NHL




## LYMPHOMAS - OS






# SOLID TUMOURS




## CNS TUMOURS




- MYELOBLASTOMAS
- EPENDYMOMAS
- PILOCYTIC ASTROCYTOMAS
- GLIOMAS
- CRANIOFARYNGEOMAS
- OTHERS

## CNS TUMOURS - OS



# NON CNS SOLID TUMOURS




6 CNS/13 NON-CNS

16 EWING (6-10)/ 5 OSTEOSARCOMAS



12 NEPHROBLASTOMAS/3 OTHERS



## NON - CNS SOLID TUMOURS - OS



RADIATION THERAPY 25% OF PATIENTS  
(>85% OF CNS TUMORS)













**THANK YOU ALL!**

